LBPH - Earnings announcements

The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini

Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older Bexicaserin demonstrated a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEEs in an interim analysis of the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Completed End of Phase 2 Meeting to discuss Longboard's global Phase 3 program for bexicaserin, which is on track to initiate in H2 2024 Longboard plans to host an Investor & Analyst Event on September 16 to highlight details of the global P

Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a conference call and we

Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in Dravet Syndrome (DS), 48.1% in Lennox-Gastaut Syndrome (LGS) and 61.2% in DEE Other was achieved Favorable safety and tolerability results Longboard is rapidly moving forward with preparations for its global Phase 3 program Conference call and webcast to be held today at 8:30am ET Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline da

• Conference call and webcast to be held tomorrow, January 2, at 8:30am ET (5:30am PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352) in participants with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin is a potentially best-in-class, oral, novel, 5-HT2C receptor superagonist with no observed impact on 5-HT2B and 5-HT2A receptor subtypes. Conference Call and Webcast Details

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Company will host a conference call at 4:30pm ET (1:30pm PT) on the same day. CONFERENCE CALL DETAILS: Live Call Participation: To join the live call by phone, please pre-register via this link, complete the brief online registration form, and select your preferred method for joining the call. Upon registering you will receive the dial-in info and a unique PIN to join the call, as well as an email confirma

Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the Technology's Broad Applicability Across Molecule Type and Therapeutic Area Appoints Life Sciences Executive, Brandi Roberts, to Board of Directors and Anthony Hickey, Ph.D. as Chief Scientific Officer Expands Leadership Team With Senior Appointments in Product Development and Manufacturing, Government and Strategic Initiatives, and Regulatory Affairs Conference Call and Webcast Scheduled Today, Thursday, March 24, 2022, at 4:30 PM ET FORT WORTH, Texas, March 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharma